Trade group AusBiotech’s 2016 Biotechnology Industry Position Survey of industry chief executives confirms biotechnology continues to be front and center of Australia’s post-mining boom economic transition.
The sector has been a pivotal contributor to Australia’s economy since it emerged over three decades ago. Yet the past year has seen increasing recognition of biotech’s growing contribution to Australia’s future wealth by government, media, local and global investors.
The 2016 Survey, conducted by AusBiotech with support from Grant Thornton and a contribution from Novotech, revealed key themes including economic value; business sentiment; finance, investment, listing and costs; and government policy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze